Mavenir CEO Welcomes Recognition of Open RAN Vendor Leadership in ABI Research Ranking
Pardeep Kohli, CEO of Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has today welcomed the new ranking by global technology intelligence company ABI Research that recognizes Mavenir as the leading vendor in Open Radio Access Network (Open RAN) solutions. In ABI Research’s detailed and independent Competitive Assessment vendor matrix, Mavenir tops all three ranking categories – market leadership, innovation and implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206233989/en/
ABI Research Open RAN Vendor Ranking November 2023 (Graphic: Business Wire)
Mavenir is classed as the leading innovator in the Open RAN space with an impressive score of 81.5 out of 100, while its achievement of 84.5 out of 100 in the implementation criteria reflects Mavenir’s central role in accelerating Open RAN deployments globally. These key rankings position Mavenir as the overall global market leader for Open RAN in the ABI Research assessment framework.
Commenting on Mavenir’s stand-out performance in the global vendor analysis, Mavenir CEO Pardeep Kohli said: “I wholeheartedly welcome this recognition of our market leadership by ABI Research, following a robust and impartial assessment of both new and incumbent players. This pole-position ranking – delivered through ABI Research’s respected and transparent process – is a significant endorsement of our dedicated mission to create the market conditions, forge the industry partnerships and deliver the technology innovation to accelerate ubiquitous and large-scale Open RAN deployments, generating powerful gains for operators and users alike.”
Using a rigorous and thorough assessment framework, ABI Research has evaluated the leading Open RAN vendors to provide a comprehensive and authoritative picture of the competitive dynamics of the Open RAN vendor ecosystem. The core areas of analysis span ten criteria, segmented across innovation and implementation clusters – including R&D activities, O-RAN Alliance contributions, support for mMIMO, recent commercial momentum, product portfolio, geographical coverage, partnerships and memberships, PoCs/trials/testing, energy efficiency commitments and brownfield deployments – concluding with an in-depth profile of the implementation and innovation strategies of the major market players.
Saqlain Ali, Senior Analyst at ABI Research remarked: “Mavenir ranked overall leader in the competitor ranking and earned the top spots for both innovation and implementation. Mavenir has demonstrated its role as a leading Open RAN vendor due to its end-to-end cloud-native software and hardware and O-RAN Alliance-compliant solutions.”
He added: “Mavenir has made significant efforts to accelerate Open RAN deployments in partnerships with other mobile, chipset vendors, and cloud providers to validate its Open RAN portfolio for multi-vendor deployments. Mavenir’s customer base is diverse, with Mavenir serving 300+ CSPs in more than 120 countries.”
The report authors highlight several areas where Mavenir is demonstrating its role as a leading industry innovator in the Open RAN domain, including its provision of end-to-end cloud-native software and hardware solutions with a comprehensive portfolio covering the core, edge and Open RAN. Further emphasized in the framework are Mavenir’s open and fully virtualized RAN (vRAN), its O-RAN Alliance-compliant solution designed to support Open RAN Functional Split (FS) options, plus Mavenir’s OpenBeam™ mMIMO portfolio, which supports both the 3rd Generation Partnership Project (3GPP) and O-RAN Alliance-compliant radios.
Mavenir’s clear commercial momentum during 2023 is a key factor in its top-ranking performance, including its announcement of multiple successful trials and new strategic partnerships with CSPs, cloud providers, and chipset vendors. The assessors particularly note the expansion of Mavenir’s geographical coverage in supporting major mobile operators with Open RAN deployment. Finally, the report draws attention to the considerable breadth of Mavenir’s partner ecosystem, plus its active collaboration with cloud providers, chipset vendors, mobile vendors, and operators to perform Open RAN integration and interoperability testing.
Notes to editors:
- ABI Research, Open RAN Vendor Assessment: Mavenir
© 2023 ABI Research. Distributed with permission of ABI Research. ABI Research Competitive Ranking, Open RAN Portfolio: November 2023
About ABI Research:
ABI Research is a global technology intelligence firm delivering actionable research and strategic guidance to technology leaders, innovators, and decision makers around the world. Our research focuses on the transformative technologies that are dramatically reshaping industries, economies, and workforces today.
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206233989/en/
Contact information
Mavenir PR Contacts:
Emmanuela Spiteri
PR@mavenir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom